Total Payments
$4,606
2024 Payments
$959.91
Companies
24
Transactions
374
Medicare Patients
5,658
Medicare Billing
$369,936
Payment Breakdown by Category
Food & Beverage$4,321 (93.8%)
Education$285.42 (6.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,321 | 370 | 93.8% |
| Education | $285.42 | 4 | 6.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $877.10 | 114 | $0 (2024) |
| ABBVIE INC. | $866.20 | 60 | $0 (2024) |
| Janssen Biotech, Inc. | $704.63 | 32 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $619.81 | 68 | $0 (2024) |
| Lilly USA, LLC | $305.01 | 21 | $0 (2024) |
| LEO Pharma Inc. | $172.56 | 25 | $0 (2022) |
| GENZYME CORPORATION | $144.04 | 9 | $0 (2023) |
| UCB, Inc. | $113.45 | 4 | $0 (2024) |
| Galderma Laboratories, L.P. | $101.33 | 6 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $97.53 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $959.91 | 61 | ABBVIE INC. ($392.61) |
| 2023 | $973.22 | 61 | Janssen Biotech, Inc. ($235.80) |
| 2022 | $738.37 | 55 | Janssen Biotech, Inc. ($204.41) |
| 2021 | $512.64 | 52 | Amgen Inc. ($247.41) |
| 2020 | $243.42 | 37 | Amgen Inc. ($231.67) |
| 2019 | $414.36 | 17 | Janssen Biotech, Inc. ($89.83) |
| 2018 | $303.30 | 33 | Novartis Pharmaceuticals Corporation ($209.57) |
| 2017 | $460.88 | 58 | Novartis Pharmaceuticals Corporation ($203.67) |
All Payment Transactions
374 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $12.22 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Dermatology | ||||||
| 12/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: Immunology | ||||||
| 11/20/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: Dermatology | ||||||
| 11/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $12.65 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | In-kind items and services | $10.42 | General |
| Category: Immunology | ||||||
| 10/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.40 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Inflammation | ||||||
| 10/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: Immunology | ||||||
| 09/25/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $10.40 | General |
| Category: IMMUNOLOGY | ||||||
| 09/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $13.43 | General |
| Category: Immunology | ||||||
| 09/17/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $11.17 | General |
| Category: Immunology | ||||||
| 09/17/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $0.63 | General |
| Category: Immunology | ||||||
| 08/30/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $8.84 | General |
| Category: IMMUNOLOGY | ||||||
| 08/30/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.39 | General |
| Category: IMMUNOLOGY | ||||||
| 08/29/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: IMMUNOLOGY | ||||||
| 08/28/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Immunology | ||||||
| 08/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: IMMUNOLOGY | ||||||
| 08/14/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $13.76 | General |
| Category: Immunology | ||||||
| 08/01/2024 | Lilly USA, LLC | TALTZ (Drug), OLUMIANT | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,340 | 2,417 | $294,719 | $84,680 |
| 2022 | 15 | 1,446 | 2,563 | $336,087 | $96,704 |
| 2021 | 14 | 1,499 | 2,790 | $335,597 | $100,115 |
| 2020 | 15 | 1,373 | 2,489 | $319,627 | $88,437 |
Total Patients
5,658
Total Services
10,259
Medicare Billing
$369,936
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 384 | 472 | $74,576 | $26,414 | 35.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 251 | 313 | $54,462 | $10,635 | 19.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 120 | 141 | $33,276 | $10,108 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 116 | 127 | $29,845 | $10,068 | 33.7% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 132 | 153 | $39,780 | $10,062 | 25.3% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 186 | 1,037 | $16,592 | $4,592 | 27.7% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 24 | 30 | $11,010 | $3,073 | 27.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $8,303 | $2,354 | 28.4% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 16 | 18 | $6,786 | $2,062 | 30.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 29 | 29 | $6,844 | $1,784 | 26.1% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 28 | 39 | $6,435 | $1,468 | 22.8% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 16 | 17 | $5,100 | $1,323 | 25.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 15 | 18 | $1,710 | $736.68 | 43.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 369 | 462 | $72,996 | $26,694 | 36.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 179 | 215 | $55,900 | $13,893 | 24.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 251 | 320 | $55,680 | $11,026 | 19.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 133 | 156 | $36,816 | $10,490 | 28.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 118 | 129 | $30,315 | $10,423 | 34.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 176 | 1,040 | $16,640 | $5,035 | 30.3% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 30 | 38 | $13,946 | $4,036 | 28.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 32 | 32 | $11,552 | $2,793 | 24.2% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 12 | 12 | $7,800 | $2,603 | 33.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 38 | 38 | $8,968 | $2,421 | 27.0% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2022 | 17 | 20 | $7,540 | $2,301 | 30.5% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 43 | 53 | $8,745 | $2,041 | 23.3% |
About Dr. Asma Ansari, M.D
Dr. Asma Ansari, M.D is a Dermatology healthcare provider based in Bloomingdale, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1114045812.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Asma Ansari, M.D has received a total of $4,606 in payments from pharmaceutical and medical device companies, with $959.91 received in 2024. These payments were reported across 374 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($4,321).
As a Medicare-enrolled provider, Ansari has provided services to 5,658 Medicare beneficiaries, totaling 10,259 services with total Medicare billing of $369,936. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Bloomingdale, IL
- Active Since 03/27/2007
- Last Updated 02/04/2015
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1114045812
Products in Payments
- Otezla (Drug) $846.24
- COSENTYX (Biological) $443.99
- SKYRIZI (Biological) $429.13
- TREMFYA (Drug) $399.91
- TALTZ (Drug) $294.59
- RINVOQ (Biological) $279.16
- REMICADE (Biological) $214.89
- DUPIXENT (Biological) $163.05
- ENSTILAR (Drug) $138.37
- DUPIXENT (Drug) $134.58
- COSENTYX (Drug) $112.04
- Sotyktu (Drug) $97.53
- Tremfya (Drug) $89.83
- VTAMA (Drug) $89.75
- HUMIRA (Biological) $77.32
- EUCRISA (Drug) $71.30
- Cimzia (Drug) $62.31
- Bimzelx (Biological) $51.14
- Humira (Biological) $38.62
- Enbrel (Biological) $30.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.